Side effects of Brodalumab

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's, Psoriatic Arthritis, and Rheumatoid Arthritis. To ensure safety and maximize the effectiveness of treatment, patients need to take Brodalumab exactly as prescribed by the doctor / pharmacist.

Brodalumab is also known by other names Siliq and Kyntheum. Brodalumab belongs to the group of monoclonal antibody drugs and is indicated for use in the treatment of inflammatory diseases such as:
Psoriasis vulgaris; Psoriatic arthritis ; Pustular psoriasis and erythroderma.

How to use: The drug is prepared in the form of a solution and used for subcutaneous injection with a weight of 210mg / 1.5ml.
Dosage:
In the treatment of moderate to severe psoriasis, adults use a dose of 210mg subcutaneously (SC) weeks 1 and 2, then a maintenance dose of 210mg SC every other day. 2 weeks. If an adequate response is not achieved after 12-16 weeks, discontinuation of Brodalumab therapy should be considered.

Common reactions such as redness, irritation or pain may occur at the injection site. Flu symptoms such as runny nose, stuffy nose, cough; fatigue, diarrhea, sore mouth/throat/muscle, fungal skin infections, itching.
Siliq reduces the body's ability to fight infections. This can put the person at greater risk for serious infections or make any infections they already have worse.
Allergic reactions when using the drug are very rare. However, if the person experiences any symptoms of a serious allergic reaction including: rash, itching, swelling (especially in areas such as face, tongue, throat); severe dizziness; If you have trouble breathing, you should notify your doctor or go to the nearest medical center for appropriate treatment.

Before using this medicine, the patient should tell the doctor the medical history, especially the diseases related to infections such as tuberculosis, intestinal tract, Crohn's disease, mental disorders, depression. Do not take Brodalumab if you are allergic to Siliq or any of its ingredients. Do not let children use the medicine. In patients treated with Brodalumab, suicidal ideation or behavior may develop. Therefore, it is necessary to carefully observe and monitor the psychology of drug users. For patients with chronic infections or a history of recurrent infections, before using Brodalumab, it is necessary to weigh the risks and benefits of the drug. If the infection is severe or does not respond to standard therapy for the infection, monitor the patient closely and discontinue the drug until the infection clears. Patients with tuberculosis should be closely monitored for signs and symptoms during/after treatment with Brodalumab. Brodaluma may influence the serum levels of several cytokines. For pregnant women: There are not enough research data on these cases, so to reduce the risk of the drug affecting the development of the fetus, the mother should consult her doctor before taking. . For lactating women: It is not known whether Brodalumab is excreted in breast milk. Therefore, consideration should be given to adverse effects on breastfed infants before use.

Abatacept: Possible increased risk or severity of side effects from Abatacept combined with Brodalumab. Abciximab, Adalimumab, Aducanumab, Aldesleukin: Increased side effects when used in combination with Brodalumab. Live Adenovirus Type 7 Vaccine: The risk or severity of infection may be increased when a live type 7 Adenovirus vaccine is combined with Brodalumab. Alefacept, Alemtuzumab, Alemtuzumab, Alirocumab: The risk or severity of adverse events may be increased when Alefacept is combined with Brodalumab. Allogeneic treated thymus tissue: When used in combination with Brodalumab, the therapeutic efficacy of Allogeneic treated thymus tissue may be reduced. Human Anthrax Immunoglobulin: The therapeutic efficacy of Human Anthrax Immunoglobulin may be reduced when combined with Brodalumab. Anthrax vaccine: The risk or severity of infection may be increased when Anthrax vaccine is combined with Brodalumab. Antilymphocyte immunoglobulin: The risk or severity of side effects may be increased when Antilymphocyte immunoglobulin is combined with Brodalumab. AstraZeneca COVID-19 Vaccine: The therapeutic efficacy of AstraZeneca COVID-19 Vaccine may be reduced when used in combination with Brodalumab. Bacillus calmette-guerin substrain with live antigen: The risk or severity of infection may be increased when Bacillus calmette-guerin substrain containing live antigen is combined with Brodalumab. Above is information about the uses, dosage and precautions when using Brodalumab. To ensure safety for your health and maximize the effectiveness of your treatment, you need to take Brodalumab exactly as directed by your doctor.